Nasdaq grants HCW Biologics extension to regain compliance with listing rules
PositiveFinancial Markets

Nasdaq has granted HCW Biologics an extension to regain compliance with its listing rules, which is a significant development for the company. This extension allows HCW Biologics more time to meet the necessary requirements, ensuring its continued presence on the stock exchange. This is important not only for the company but also for its investors, as it reflects Nasdaq's support and provides a pathway for HCW to stabilize and potentially grow.
— Curated by the World Pulse Now AI Editorial System